CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 200 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2024. The put-call ratio across all filers is 1.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,644,977 | -46.3% | 125,506 | -39.1% | 0.01% | -50.0% |
| Q1 2024 | $8,652,703 | +385.2% | 206,164 | +358.5% | 0.01% | +366.7% |
| Q4 2023 | $1,783,431 | +1407.4% | 44,968 | +946.0% | 0.00% | – |
| Q3 2023 | $118,308 | -94.9% | 4,299 | -93.8% | 0.00% | -100.0% |
| Q2 2023 | $2,335,979 | +4.8% | 68,847 | +11.1% | 0.01% | -20.0% |
| Q1 2023 | $2,228,781 | +48.5% | 61,945 | +84.0% | 0.01% | +25.0% |
| Q4 2022 | $1,500,850 | +614.7% | 33,674 | +350.4% | 0.01% | +700.0% |
| Q3 2022 | $210,000 | -84.3% | 7,476 | -88.5% | 0.00% | -95.2% |
| Q1 2021 | $1,337,000 | -55.4% | 64,913 | -62.1% | 0.02% | -51.2% |
| Q4 2020 | $3,001,000 | +175.1% | 171,318 | +132.8% | 0.04% | +168.8% |
| Q3 2020 | $1,091,000 | +131.1% | 73,584 | +102.5% | 0.02% | +128.6% |
| Q2 2020 | $472,000 | – | 36,334 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,388,967 | $125,425,669 | 9.68% |
| 5AM Venture Management, LLC | 497,270 | $18,403,963 | 4.12% |
| COMMODORE CAPITAL LP | 1,425,000 | $52,739,250 | 3.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 374,910 | $13,875,419 | 3.27% |
| TSP Capital Management Group, LLC | 249,220 | $9,223,635 | 2.89% |
| Eventide Asset Management | 3,327,132 | $123,137,155 | 2.11% |
| Affinity Asset Advisors, LLC | 475,400 | $17,594,554 | 2.03% |
| Novo Holdings A/S | 850,000 | $31,458,500 | 1.83% |
| Bellevue Group AG | 2,971,615 | $109,979,471 | 1.79% |
| Redmile Group, LLC | 718,723 | $26,599,938 | 1.61% |